The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study
Launched by MICHEL ADAMINA, MD · Jul 22, 2021
Trial Information
Current as of June 07, 2025
Suspended
Keywords
ClinConnect Summary
Anastomotic insufficiency leads to clinical strains for patients, and significantly increases morbidity and mortality. On average, hospital stay is extended by 12 days while healthcare-related expenses are increased by 30,000 USD when patients suffer from an anastomotic leak. In experienced centers, the approximated incidence of anastomotic insufficiency is 3,3% for colon and 8.6% for colorectal procedures. Multiple subgroups of patients with increased risk for anastomotic leaks have been described in previous publications. Meticulous preoperative recognition of patients with increased risk...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who underwent colon or colorectal anastomosis for neoplasia, diverticulitis, mesenterial ischemia, iatrogenic or traumatic perforation, or inflammatory bowel disease
- Exclusion Criteria:
- • age \< 18
- • recurrent colorectal cancer
- • peritoneal carcinomatosis or unresectable metastatic disease at time of bowel resection
- • informed consent not obtainable
- • follow-up \< 6 weeks after surgery
- • no reversal of and ostomy
About Michel Adamina, Md
Dr. Michel Adamina, MD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With extensive expertise in his field, Dr. Adamina leads innovative clinical studies that explore novel therapeutic approaches and enhance understanding of various health conditions. His dedication to ethical research practices and patient safety underpins all trials conducted under his sponsorship, fostering collaboration with leading medical institutions and contributing to the development of evidence-based treatments. Dr. Adamina's work not only drives scientific progress but also aims to translate research findings into tangible benefits for patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winterthur, Zürich, Switzerland
Allschwil, Basel, Switzerland
Patients applied
Trial Officials
Michel Adamina, Prof. Dr. med.
Study Chair
Clinical Research and Artificial Intelligence in Surgery, Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland
Anas Taha, Dr. med.
Principal Investigator
None currently
Thomas Steffen
Principal Investigator
Cantonal Hospital of St. Gallen
Stephanie Taha-Mehlitz, Dr. med.
Principal Investigator
Department of Visceral Surgery, Clarunis, University Hospital Basel, Basel, Switzerland
Frédéric Ris, Prof. Dr. med.
Principal Investigator
Department of Surgery, Hôpitaux Universitaires de Genève
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials